Statins: Widely used drugs may protect people from air pollution
By Brian Bienkowski
Environmental Health News
Nov. 24, 2014
One of the most widely prescribed drugs in the United States may have an extra benefit: protecting people from air pollution.
Statins, prescribed to lower cholesterol and reduce risks of heart attacks and strokes, seem to diminish inflammation that occurs after people breathe airborne particles.
“Health impacts from spikes in particulates in the air are substantial. Statins seem to protect not only lungs from these impacts but the heart, too,” said Dr. Norman Edelman, the American Lung Association's senior medical advisor.
About one in four Americans over the age of 45 takes statins, including Lipitor, Zocor and other brand names.
Although drugs cannot be prescribed to protect people from air pollution, several studies show that people who take statins have fewer proteins in their blood that indicate inflammation of tissues, said Dr. Stephan van Eeden, an associate professor at the University of British Columbia who specializes in lung health. This inflammation may aggravate respiratory and cardiovascular diseases.
Most recently, a study of 1,923 U.S. women found that those taking statins are less likely to have signs of inflammation, said Bart Ostro, an epidemiologist with California’s Office of Environmental Health Hazard Assessment who led the study.
“There are some specific groups [such as diabetics] that seem to have higher levels of inflammation after long-term exposure,” Ostro said. “On the converse side, we found that people on statins seem to be protected from the inflammatory effects of PM2.5.”
In the women taking statins, there was no association between PM2.5 – the tiny particles emitted mostly by burning diesel and other fossil fuels – and the proteins indicating inflammation, while for most of the other groups the links were quite strong.
It’s not the first time researchers have noticed this link: University of Michigan researchers found decreased blood indicators of inflammation in people who took statins in a study of 92 people in Boston. A national study of 5,778 people also reported that statins canceled out the presence of signs of inflammation from PM2.5, carbon monoxide and nitrogen dioxide.
Scientists believe that inflammation is a key factor in heart disease.
“The older thinking was that plaque in coronary arteries caused heart attacks,” Edelman said. “Now the thinking is that it’s also due to some living tissue under plague that gets inflamed and that disrupts the plaque. We already knew statins ameliorate heart disease, and always thought it was through lipids, but here’s a new pathway.”
Around the world, studies have shown that whenever particulates increase, deaths from heart attacks and respiratory disease rise, too. Experts estimate that fine particles are linked to about 800,000 deaths annually worldwide.
Particulate pollution has been on a steady decline in the United States: The national average for PM2.5 decreased 34 percent from 2000 to 2013, according to the Environmental Protection Agency. However, high concentrations of the pollution still persist in some cities with heavy traffic and industry, such as Los Angeles and Chicago.
When van Eeden and colleagues gave statins to rabbits before exposing them to particulate matter they had decreased lung inflammation. In a second study of rabbits, statins seemed to help clear large particles from the lungs by promoting the movement of white blood cells to nearby lymph nodes, which protects the lungs against pending inflammation.
“It’s clear that if the animals are treated for about a month with statins before they’re exposed to particles, you can significantly lower the amount of particles generated in the lungs and decrease the blood vessel inflammatory process,” van Eeden said.
It’s not clear how statins may cause fewer particles in the lungs, but van Eeden said statin-treated rabbits have more particles in lymph nodes, suggesting the drugs stimulate particles to move to the nodes.
In another animal test mice given Zocor prior to oil fly ash or particulate exposure did not experience lung injuries and inflammation like their non-treated counterparts did, according to a 2011 study in Argentina.
Van Eeden and colleagues are now trying to figure out if the animal findings hold true for human lungs. So far, their work looks “very promising,” he said.
His lab is examining lung tissue from people who had part of a lung removed. Many were smokers and had a lot of particles in their lungs. They haven’t finished the study but so far they’re seeing that “it’s quite clear that people who used statins had less particles in their lungs,” van Eeden said.
“Once again it suggests anti-inflammatory properties and seems to clear the particles,” van Eeden said. “And these were people chronically exposed to air pollution or cigarette smoke.”
However, it’s too early for doctors to prescribe statins for people exposed to air pollution, said Dr. Martha Daviglus, a cardiovascular epidemiologist at Northwestern University and University of Illinois.
“We need more evidence. We already have a lot of people taking statins for cholesterol, and we don’t fully know the effect of taking the drugs for years and years, and decades yet,” Daviglus said.
|University of British Columbia|
The number of people taking the drugs is already expected to rise as the American Heart Association last year advocated for increased statin use to combat high cholesterol.
It remains unclear if people would have to take statins immediately prior to breathing air pollution, and, if so, for how long, in order for the drugs to help.
“It seems they have some good effects with regards to air pollution, but we need to conduct clinical trials with people living near roads or high-emitting facilities,” Daviglus said.
Ostro said it would be “somewhat of a leap” to prescribe statins to mitigate air pollution impacts, given some of their known side effects, such as liver problems.
Food and Drug Administration spokesman Kristofer Baumgartner said that any new claims about additional benefits for a drug have to be reviewed by a team of scientists, and the benefit would have to outweigh any risks.
Two pharmaceutical giants who sell statins, Pfizer and AstraZeneca, would not comment on the air pollution studies.
There is no research on whether other anti-inflammatory drugs, such as ibuprofen, would also protect people from air pollution.
Van Eeden sees potential for statins to play a role in reducing effects of air pollution, possibly in the near future. One possible group could be those suffering from asthma, which causes inflamed and constricted air passages.
“If this human study confirms what we found in rabbits, then if there is an episode of air pollution, maybe people at high risk can get a short course of statins for that period until the air pollution clears,” he said. He is currently seeking funding to test statins on firefighters to see if they reduce lung inflammation caused by smoke.
Edelman said the answer to protecting people is still cleaning the air.
“We don’t want people to start thinking now we have a drug to control effects of air pollution so we don’t have to worry about air pollution,” he said. “It’s still a large threat.”
Follow Brian Bienkowski on Twitter.
EHN welcomes republication of our stories, but we require that publications include the author's name and Environmental Health News at the top of the piece, along with a link back to EHN's version.
For questions or feedback about this piece, contact firstname.lastname@example.org.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Recent Environmental Health News coverage